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Abstract
Background: Identiﬁcation of drug-drug and drug-diseases interactions can pose a diﬃcult problem to cope with, as
the increasingly large number of available drugs coupled with the ongoing research activities in the pharmaceutical
domain, make the task of discovering relevant information diﬃcult. Although international standards, such as the
ICD-10 classiﬁcation and the UNII registration, have been developed in order to enable eﬃcient knowledge sharing,
medical staﬀ needs to be constantly updated in order to eﬀectively discover drug interactions before prescription.
The use of Semantic Web technologies has been proposed in earlier works, in order to tackle this problem.
Results: This work presents a semantic-enabled online service, named GalenOWL, capable of oﬀering real time
drug-drug and drug-diseases interaction discovery. For enabling this kind of service, medical information and
terminology had to be translated to ontological terms and be appropriately coupled with medical knowledge of the
ﬁeld. International standards such as the aforementioned ICD-10 and UNII, provide the backbone of the common
representation of medical data, while the medical knowledge of drug interactions is represented by a rule base which
makes use of the aforementioned standards. Details of the system architecture are presented while also giving an
outline of the diﬃculties that had to be overcome. A comparison of the developed ontology-based system with a
similar system developed using a traditional business logic rule engine is performed, giving insights on the
advantages and drawbacks of both implementations.
Conclusions: The use of Semantic Web technologies has been found to be a good match for developing drug
recommendation systems. Ontologies can eﬀectively encapsulate medical knowledge and rule-based reasoning can
capture and encode the drug interactions knowledge.
Background
One of the health sectors where intelligent information
management and information sharing compose valuable
preconditions for the delivery of top quality services, is
personalized drug prescription. This is more evident in
cases where more than one drug is required to be pre-
scribed, a situation which is not uncommon, as drug
interactions may appear. The problem is magniﬁed by
the wide range of available drug substances in combina-
tion with the various excipients in which the former are
present. Another factor that makes drug prescription a
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complex task is the complexity that characterizes the deﬁ-
nition of possible interactions or contraindications due to
the large number of parameters that are implicated.
Indicatively, it is mentioned that, according to statis-
tics, men over 55 years old, daily consume four diﬀerent
medicines on average and the reactions that can occur due
to combined prescription are diﬃcult to predict. As an
example, the substance Donepezil (ATC code: N06DA02)
which is prescribed for the treatment of Alzheimer’s dis-
ease interacts with 9 other substances and 3 other dis-
eases. If it is taken into account that there exist more
than 18,000 pharmaceutical substances, including their
excipients, then it is clear that the continuous update of
health care professionals is remarkably hard. Over this,
the extensive literature makes discovery of relevant infor-
mation a time consuming and diﬃcult process, while the
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diﬀerent terminologies that appear between sources add
more burden on the eﬀorts of medical professionals to
study available information.
Semantic Web technologies can play an important role
in the structural organization of the available medical
information in a manner which will enable eﬃcient dis-
covery and access. Semantic Web has already inﬁltrated
in the public health sector [1] as a mean for representa-
tion of available knowledge or through the utilization of
reasoning methodologies for automating procedures such
as diagnosis, data classiﬁcation, medical record consolida-
tion, etc.
More speciﬁcally, with the use of ontology languages
such as OWL, a rather large amount of biomedical ontolo-
gies have been developed among them ontologies of large
size such as the Biological Pathways Exchange (BioPax)
[2], the GALEN ontology [3], the Foundational Model of
Anatomy (FMA) [4] as well as the Gene Ontology [5] and
SNOMED CT [6].
The use of OWL for the expression and representation
of the aforementioned ontologies, apart from the beneﬁts
regarding knowledge reuse and sharing that come from
the use of a standardized language, revealed the beneﬁts
of semantic reasoning. The validation of the ontologies
using OWL reasoning engines revealed important mod-
elling failures but also a large number of subsumption
relations that were missing from the initial requirements
and not locating them would mean the loss of information
in patient management systems.
Research projects funded for enabling Semantic Web
technologies in the diagnosis and therapeutic procedures
exist such as TUMOR [7], REMINE [8] and PSIP [9], with
the latter aiming at reducing drug prescription adverse
eﬀects through data mining and semantic interpreta-
tion of a patient’s medical record. Other projects like
NeOn [10] and Active Semantic Documents [11] employ
ontologies in daily medical practice. Despite the research
activity, there have been few proposals for a systematic
development of a semantic knowledge base which will
aid physicians when prescribing drugs. [12] describes a
framework for information integration for drug safety
determination using ontologies and in [13] authors sug-
gest an approach to semantically annotate Electronic Dis-
charge Summaries in order to provide decision support to
physicians.
The paper presents GalenOWL, a semantic-enabled
system for discovering drug recommendations and inter-
actions. GalenOWL makes use of established and stan-
dardized medical terminologies together with a rich
knowledge base of drug-drug and drug-diseases interac-
tions expressed as rules and OWL axioms. GalenOWL
is implemented as an online service having in mind,




The stimulus for developing GalenOWL was given by an
already available market product. The GALINOS drug
guide, available at http://www.galinos.gr in Greek, is an
online service where a user can query the drug database
and get information on available drugs that are found in
the market, e.g. indications, recommended dosage, excip-
ients, interactions, adverse eﬀects, etc, where all the latter
are related to the drugs active substances. All the above
were mined after extensive research in the literature and
of available documents such as Summary of Product Char-
acteristics (SPC) and Patient information leaﬂets (PIL).
For enabling this kind of functionality, GALINOS employs
international medical standards which allow a unique
identiﬁcation of diseases and substances. It was evident
that the knowledge integrated in the service could be used
in order to develop an intelligent system for oﬀering drug
recommendations.
GalenOWL architecture can be seen in Figure 1. The
user issues queries to the system in order to ﬁnd drug
indications and contraindications that match patient data.
These data populate the knowledge base and rule-based
reasoning is performed. The reasoning engine makes use
of the medical ontologies and the rule base for drug rec-
ommendations and a list of the drug recommendations
(indications and contraindications) is returned by the
engine. GalenOWL is novel in its ﬁeld as, to the authors
knowledge, there are no commercial systems that oﬀer
drug-diseases interactions. Systems that oﬀer drug-drug
interactions are available such as the one oﬀered by
Drugs.coma.
In GalenOWL, a drug-disease interaction, i.e. an
(adverse) interaction between a drug and a disease, is
deﬁned if one of the following 3 facts hold: a) a drug
that is administered for a particular disease may aﬀect
the progress of another disease. For example a drug for
treating an upper respiratory infection should not be
prescribed to a patient with renal failure if that drug
aggravates renal function, b) the existence of a disease
may aﬀect the pharmacokinetics of a drug, e.g. a disease
could increase a drug’s catabolism, thus reducing its eﬀec-
tiveness, or it could reduce its metabolism, thus causing
accumulation of the drug in the body and lead to toxic
reactions, c) precise contraindications where a drug can-
not be prescribed for a patient that suﬀers from a speciﬁc
condition, e.g. an anticoagulant drug cannot be prescribed
to a patient that shows signs of internal bleeding.
Development details
For the OWL/XML serialization, the Jena Semantic
Web Frameworkb was used. The OWL reasoner which
provided the drug recommendations is OWLIM-Litec
together with Sesamed for providing the REST interface,
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Figure 1 GalenOWL usage. Usage of the GalenOWL system showing processing and information ﬂow.
the RDF data access and management platform and the
SPARQL query interpretation layer. OWLIM was chosen
as it has been found as one of the most eﬃcient OWL
reasoners [14,15].
International standards ontologies
In order to provide such a service, coupling of Semantic
Web and medical terminologies was needed. GalenOWL
is built on top of OWL ontologies which express interna-
tional standards of medical terminology in order to pro-
cess requests for drug recommendations. The following
terminologies are expressed as OWL ontologies:
• ICD-10:The World Health Organization
classification of diseases. It is used in GalenOWL for
unique identification of diseases thus uniquely
identifying drug indications and contraindications
related to diseases.
• UNII: Unique Ingredient Identifier. Used for the
identification of active ingredients found in drugs. In
GalenOWL it is used for uniquely identifying drug
indications and contraindications related to
ingredients.
• ATC: The Anatomical Therapeutic Chemical
Classification is used for the classification of drugs. In
GalenOWL it is used in similar fashion to UNII.
Each code in the above encodings is expressed as an
OWL class.
Domain ontologies
Besides these international standards, two more classiﬁ-
cations are expressed in OWL in order to make easier use
of the system:
Substance: As the use of encodings for drug ingredi-
ents is not convenient for humans, the identiﬁcation of
active substances is done using its common name refer-
ences in medical bibliography. These names come from
international standards such as the International Nonpro-
prietary Names (INN) and others such as USAN (United
States Adopted Name) or BAN (British Approved Name).
Members of this identiﬁcation list are substances such
as acetazolamide or isradipine. In addition, substances
correspond to ATC codes and this is captured in the
ontology through class equivalence such that for example
acetazolamide ≡ S01EC01.
Condition: As certain “groups” of substances and/or dis-
eases are frequently present in drug interactions and these
groups are not recorded explicitly in any standardized
classiﬁcation, it is more convenient for medical use to
specify these custom groups. These often used groups
are termed “conditions” in GalenOWL and are deﬁned by
medical experts. An example of such condition is barbitu-
ratesdrugs which is deﬁned as
barbituratesdrugs = a/N01AF | a/N01AG | a/N03AA |
a/N05CA | a/N05CB | a/N05CX
where “a/” stands for ATC code and “|” stands for “or”.
So any member of these premises is also a member of
barbituratesdrugs. In addition a condition can appear as a
premise in other condition deﬁnitions. So the condition
hemorrhage-postoperative = c/hemorrhage-nos &
c/surgical-dental-procedures
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is satisﬁed when two other Conditions (denoted by
“c/”) are satisﬁed simultaneously (denoted by “&”
which stands for “and”). It is evident that condi-
tions can be eﬀectively expressed in OWL as deﬁned
classes. In the above examples, “a/” or “c/” would rep-
resent the namespace of the ontology and “|” or “&”
would represent the union or intersection of classes
respectively. Using DL notation the above classes are
represented as
barbituratesdrugs ≡ N01AF unionsq N01AG unionsq N03AA unionsq




In order to automate the deﬁnition of the Conditions
ontology, a parser was developed to express the conditions
from the custom format explained above to OWL/XML
notation.
All the abovementioned ontologies were imported from
the GalenOWL core ontology depicted in Figure 2. Addi-
tionally, Patient is the class for patient instances. Patient
instances are related with theMedicalDefinitions and with
AgeGroup and SexGroup through the hasAgeGroup and
hasSexGroup properties respectively.
Rule base
After the deﬁnition of the domain ontologies and the core
ontology, an appropriate rule base for indications and
contraindications was deﬁned. The rules are expressed
in a custom language similar to the Conditions of the
previous subsection. These rules however usually have a
more complex syntax. An example rule for the indication
of rimonabant is deﬁned as
rimonabant = i/E65-E68 & (i/E11 | i/E78)
where “i/” stands for ICD-10 code and it reads as: rimon-
abant is indicated in cases where E65-E68 and, E11 or
E78, diseases are present. In DL this is represented as
“rimonabant ≡ E65-E68  (E11 unionsq E78)”.
Due to GalenOWL being developed using OWLIM-
Lite, the above expression had to be expressed in
the OWLIM custom rule language. “or” could not be
expressed in a rule, so two diﬀerent rules were generated
for rimonabant. To make things more complicated, drug
indications also depend on the patient’s sex and age. In the
above example, rimonabant is prescribed only for adults
or elder patients so this also had to be encoded in the rules.
As a result, 4 rules were built for rimonabant indication
(gl: stands for the GalenOWL namespace), i.e.
1) Patient(?p), hasData(?p, icd:E65-E68), hasData(?p,
icd:E11), hasAgeGroup(?p, gl:adult) → canTake(?p,
sub:rimonabant)
2) Patient(?p), hasData(?p, icd:E65-E68), hasData(?p,
icd:E78), hasAgeGroup(?p, gl:adult) → canTake(?p,
sub:rimonabant)
3) Patient(?p), hasData(?p, icd:E65-E68), hasData(?p,
icd:E11), hasAgeGroup(?p, gl:elder) → canTake(?p,
sub:rimonabant)
4) Patient(?p), hasData(?p, icd:E65-E68), hasData(?p,
icd:E78), hasAgeGroup(?p, gl:elder) → canTake(?p,
sub:rimonabant)
Of course, indication rules have no limitation in the
premises separated by “or” which can lead to a very big
Figure 2 GalenOWL core ontology. Diagram displaying the main classes of the GalenOWL ontology along with their properties.
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rule expansion. As an example, buspirone has 13 premises
separated with “or” which leads to 13 diﬀerent rules.
In the current version of GalenOWL 1342 substance
indications/contraindications were expressed using 9266
rules. A parser similar to the one developed for Condi-
tions was used in order to express the indications in the
OWLIM custom rule language. Although the rule base is
quite large in size, OWLIM’s sophisticated indexing struc-
ture and rule engine was quite fast in evaluation of rule
activation.
Another rule that was necessary is one that would
evaluate the conﬂicts between indications and con-
traindications regarding a patient’s conditions. For exam-
ple, a substance could be indicated in the case of
a speciﬁc disease but the same substance could also
be contraindicated in the case of another disease.
This will result in substance appear both in the indi-
cations and contraindications. Clearly this substance
should be excluded from the recommended prescrip-
tion. In order to discover these substances, a special rule
was expressed as “canTake(?p, ?s), cannotTake(?p, ?s) →
hasSubstanceConflict(?p, ?s)” and was incorporated in the
rule base.
Finally, for each rule an instance under Indications or
ContraIndication class (both subclasses of SubstanceRec-
ommendations) is created and the property hasTextual-
Representation is set to the original textual representa-
tion of the rule. This is used in order to provide tracing
in rule matching so that for each rule that is activated
the property activatedRule(patient, recommendation) is
materialized. These relations are depicted in Figure 2. In
the GalenOWL ontologies a total of 28,867 named classes
were deﬁned. Table 1 gives information about the size of
the ontologies imported in GalenOWL.
Interface and querying
The interface to the system is depicted in Figure 3. As the
focus on the system was on the functionalities that can be
provided and on its capabilities, the design of the interface
may lack in aesthetic design nevertheless it provides all the
Table 1 GalenOWLontology metrics








Number of primitive and deﬁned classes in the GalenOWL ontologies
information that are returned from the system in a rather
easy to use layout.
Patient data regarding diseases, allergies, population
group and current medication are entered sequentially
using the form. After all data are entered, the user submits
all information to the system in order to be inserted in the
knowledge base as an RDF graph which represents patient
data. During insert, all inferences using OWL reasoning
and rule execution are performed and are also stored in
the knowledge base thus making query answering faster
as no complex inference is performed during query time.
Recommendations lists from GalenOWL are retrieved
using separate SPARQL queries (querying for indications,
contraindications and conﬂicts) which are sent from the
user interface to the Sesame server through REST.
In order to provide an overall view of the drug recom-
mendations that are returned by GalenOWL the following
sequence of actions is performed: Each patient data (dis-
ease, allergy, current medication) that is in the list is
inserted separately and inference is performed. This is
done so that the user can have a list of recommendations
that is due to each data separately. In a ﬁnal step all data
are entered simultaneously so that recommendations that
are valid for all patient’s data are evaluated. All recommen-
dations are separated in 4 groups, the indications list, the
contraindications list, the conﬂicts between indications
and contraindications, i.e. substances that appear both in
indications and contraindications which can be expressed
as (indications ∩ contraindications), and a cleared list
where only indications that do not appear in contraindi-
cations are present. This list actually represents the valid
recommendations of the system for the patient’s prescrip-
tion, i.e. indications \ (indications ∩ contraindications).
Results lists are separated in tabs and each tab corre-
sponds to one of the sequential steps described above.
For easing the burden to the query engine, the last set
of valid recommendations is composed programmatically
from the user interface by comparing and combining the
indications and conﬂicts lists.
Business logic implementation
For having a broader view of GalenOWL’s performance,
a similar system has been developed using standard busi-
ness logic programming technologies. This system has
been termed GalenDrools as in its core for drug recom-
mendations lies the Drools rule engine [16], which is an
open source and eﬃcient framework for business logic
integration.
To give a brief description of GalenDrools implemen-
tation, ICD-10, ATC and UNII encodings as well as
Substance and Conditions, are stored in a database. For
building the rule base the indications/contraindications
rules are parsed and translated to the Drools rule language
(DRL). When premises for ICD-10 or ATC classiﬁcation
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Figure 3 User interface and results. Snapshot of the prototype user interface..
codes are present in the rule body, the latter is automat-
ically populated with upper level codes of the classiﬁca-
tion, in a manner similar to the Class/SubClass relation
in ontologies. One more diﬀerent aspect of GalenDrools
architecture is the way that Conditions are handled.
While in GalenOWL Conditions are translated into OWL
deﬁned classes, here each condition that appears in a rule
is recursively expanded to its primitive elements, i.e. ICD-
10, ATC, UNII or Substance codes. As an example, let
us assume a rule for prescribing the substance mefenamic
where it states:
mefenamic = c/arthropathy-inﬂammatory-indication |
i/N94.4 where “arthropathy-inﬂammatory-indication =
i/M05-M14 | i/M15-M19”. The DRL rule would have to
be expanded in order to take into account the Condition




p: Patient((data==M05-M14) || (data==M15-M19) ||
(data==M00-M99) || (data==N00-N99) ||




In the above rule, one can notice how the expansion
of both the Condition deﬁnition and of the class/subclass
relations is performed. This knowledge, although it is
already stored in the database, it has to be separately
declared inside the rule expression.
When requesting drug recommendations, patient data
are inserted as facts in the Drools truth maintenance table
and rule execution is initiated. These facts actually corre-
spond to the database IDs of the ICD-10, ATC, UNII and
Substance codes which makes rule matching quite fast.
Results and discussion
GalenOWL performance
In order to verify GalenOWL’s functionality in terms of
results completeness in drug recommendations, a series
of random queries regarding patient data (diseases, cur-
rent medication, population groups, etc.) were submitted
to the system and the results were evaluated by a med-
ical expert. The analysis concluded that the results were
as expected and all patient’s conditions were taken into
account. A series of tests in order to determine initial-
ization time, memory consumption and query response
time of GalenOWL have been performed. These values
are reported in the ﬁrst row of Table 2 where promising
Table 2 GalenOWL vs GalenDrools
Initialization Memory Query time
GalenOWL 148 s 649 MB 16 ms
GalenDrools 41 s 74 MB 5 ms
GalenOWL performance compared to a similar system developed in Drools
(GalenDrools).
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results are reported especially in query response time
which is kept at a satisfying 16 ms average time. The
initialization phase, which included compilation of the
rule base and loading of the ontology in the main memory
took 148 seconds which is reasonable if the large volume
of the knowledge base (ontologies plus rules) is taken into
account and the fact that this is a one time task executed
only during initialization. What is less than ideal is the
memory consumption after the initialization phase which
stays constant at around 649 MB and takes up a fairly
big amount of system resources which is undesirable in a
production environment.
GalenOWL compared to GalenDrools
As it is depicted in Table 2, a direct comparison between
GalenOWL and GalenDrools reveals that in almost all
aspects the business logic implementation of the drug rec-
ommendations system outperforms the semantic-enabled
implementation by an order of magnitude. Initialization
of GalenOWL takes more time as the rule base has to be
compiled and all inferences computed during the ontol-
ogy loading. Memory consumption is high as the whole
ontology and rule base have to be loaded in memory.
On the contrary, in GalenDrools the initialization phase
includes only the compilation of the rule base which
is the only structure stored in memory thus making it
more eﬃcient both in startup time and in memory con-
sumption. Regarding query response time, in GalenOWL
when a new patient instance is inserted, inference is
performed which leads to increased response time com-
pared to GalenDrools where simple rule matching is
performed.
On the other hand, although inference adds burden and
overhead to query response, it actually makes develop-
ment of the system easier. In the business logic imple-
mentation both the subclass relations and the expansion
of Conditions had to be implemented programmatically
and encoded in the rule body, a process which requires
eﬀort and increases the possibility to induce errors, but
it also combines medical knowledge, e.g. from Conditions
deﬁnition, with drug administration rules. In contrast, in
the OWL-based implementation, issues such as hierar-
chical class relationships and derived consequences such
as class membership, were automatically identiﬁed by
the reasoning engine and medical knowledge is deﬁned
solely in the ontology. The pharmaceutical knowledge
is separately expressed in the rules. Additionally, the
GalenOWL implementation promotes knowledge sharing
as the ontologies that were developed can be accessed
by using Semantic Web technologies, e.g. they can be
exposed as SPARQL endpoints and queries can be issued.
In GalenDrools, since a database back-end is used for stor-
ing knowledge, exposing this information is not straight-
forward and queries to the database have to follow the
schema, which is not easy to expose. Finally, regarding
the rule deﬁnitions, the GalenOWL approach directly
express the pharmaceutical knowledge using rules and
the latter can be directly loaded to any ontology rea-
soner. In the GalenDrools approach, the rules have to
be processed so that the entity relationships and hierar-
chies are materialized inside the rule body. This makes
rule deﬁnition speciﬁc to the business rule engine which
will be used. Taking into account all the above, we can
conclude that ontologies provide a good match for such
systems as they can eﬀectively integrate knowledge and
inherently make it available for further use. Table 3
summarizes the qualitative comparison between the two
approaches.
The eﬃciency of production rule engines has already
been utilized in Semantic Web literature. In [17] the
authors use the CLIPS rule engine as an OWL reasoner
after transforming theOWL ontology to the COOL object
oriented language of CLIPS. However ontology manage-
ment and querying become demanding tasks. In OWL-
JessKB [18] the Jess rule engine is used for OWL reasoning
where the RDF triples are inserted as facts and OWL
entailments are materialized using production rules. This
approach though suﬀers from memory limitations. It




Yes, ontology based. Partial, relational DB.
Medical knowledge inte-
gration and reusability
Hierarchical class relationships (ICD10, UNII, ATC) and
deﬁnition of Conditions are expressed using OWL
expressivity. They can be utilized by any OWL rea-
soner.
ATC, UNII, ICD10 entities relationships and Conditions
are materialized inside rule expressions. Materializa-
tion is speciﬁc to the rule language used.
Knowledge sharing Ontology can be published and accessed through SW
technologies, e.g. as a SPARQL endpoint.
Queries to DB have to follow the DB schema.
Rule expression Rules for drug recommendations directly express
pharmaceutical knowledge and can be immediately
loaded to a reasoner.
Rules express pharmaceutical knowledge but have
to be post processed, in order to materialize entities
relationships before loading them to the rule engine.
Table summarizing the major qualitative diﬀerences between GalenOWL and GalenDrools.
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should be noted that business rule engines have been
around for much longer time than OWL reasoners and
they are aimed at much larger audience than Seman-
tic Web technologies. This alone corresponds to a much
larger community contributing to frameworks like Drools.
These two facts can account for the exceptional perfor-
mance that these systems exhibit. The authors believe
that as the Semantic Web community grows larger, more
frameworks that will be able to compete traditional rule
engines will be made available. OWLIM is an example
of an eﬃcient reasoning engine and up to now several
other reasoners are claiming increased performance such
as HermiT [19] and TrOWL [20].
Conclusion
In this paper a drug recommendation system based on
SemanticWeb technologies, termed GalenOWL, was pre-
sented. It has been shown that OWL and Semantic Web
technologies can provide a good match for drug recom-
mendations as OWL is expressive enough to eﬀectively
encapsulate medical knowledge. Rule-based reasoning
can model medical decision making and provide assis-
tance to experts. A comparison of the semantic-enabled
implementation to a traditional business logic imple-
mentation was presented. Although the latter has shown
better performance in time and memory requirements,
semantic technologies provide a better alternative for
integrating knowledge in the system than simple rule
engines.
Future work, apart from the expansion of the seman-
tic rule base, will include prioritization of interactions so
not all interactions have the same importance. Additional
work will be directed to research oriented performance
optimizations, such as context extraction from medical
knowledge and from queries which will lead to modu-
lar ontologies, so that not to take into account the whole
ontology during query time. This will result in less mem-
ory utilization and better query response times.
Endnotes
aDrugs .com, http://www.drugs.com/drug interactions.
php.
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